Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD

Next Previous
Trial Profile

HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bleomycin; Cyclophosphamide; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Prednisone; Prednisone; Procarbazine; Vincristine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HD21 (advanced stage)

Most Recent Events

  • 03 Jun 2025 According to a Takeda media release, based on positive results of this study, the European Commission (EC) approved ADCETRIS (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) - in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. This decision marks the second approval for an ADCETRIS-based combination regimen for frontline Hodgkin lymphoma.
  • 10 Dec 2024 Results (n=84) presented at the 66th American Society of Hematology Annual Meeting and Exposition.
  • 25 Nov 2024 According to a Takeda media release, data from the Phase 3 HD21 study will get featured in four presentations at the 66th American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2024, in San Diego, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top